{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-26-000037","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2026-05-13T11:34:07+00:00","discovered_at":"2026-05-13T11:35:00.272589+00:00","generated_at":"2026-05-13T11:36:38.941040+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Altimmune Q1 net loss $22.6M; cash $535M; PERFORMA Phase 3 MASH trial initiation in H2 2026","bullets":["Net loss of $22.6M ($0.18 loss per share) vs $19.6M ($0.26) in Q1 2025; R&D $16.2M, G&A $8.1M.","Cash, equivalents and short-term investments $332M at Mar 31, 2026; $535M at Apr 30, 2026 after $225M public offering.","Initiation of PERFORMA Phase 3 MASH trial planned for H2 2026; topline RECLAIM Phase 2 AUD data expected Q3 2026; RESTORE Phase 2 ALD enrollment completion Q3 2026.","Pemvidutide received Breakthrough Therapy Designation for MASH; EASL presentations on May 28, 2026 including 48-week IMPACT data."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-26-000037","json":"https://secwatch.observer/filing/0001326190-26-000037.json","markdown":"https://secwatch.observer/filing/0001326190-26-000037.md","text":"https://secwatch.observer/filing/0001326190-26-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/0001326190-26-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T11:36:38.941040+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8b80a13f003dfd9e397a5edd9679adb9ed599f4","claim":"Altimmune, Inc. reported the first quarter ended March 31, 2026 results: net income $22.6 million, or $0.18 net loss per share.","evidence_excerpt":"Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/0001326190-26-000037-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"$22.6 million, or $0.18 net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}